USRE35568E - Method for fluorodecarboxylation - Google Patents
Method for fluorodecarboxylation Download PDFInfo
- Publication number
- USRE35568E USRE35568E US08/340,960 US34096094A USRE35568E US RE35568 E USRE35568 E US RE35568E US 34096094 A US34096094 A US 34096094A US RE35568 E USRE35568 E US RE35568E
- Authority
- US
- United States
- Prior art keywords
- group
- carboxylic acid
- halogenated
- fluorinated
- acid compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 49
- -1 aliphatic carboxylic acid compound Chemical class 0.000 claims abstract description 42
- FQFKTKUFHWNTBN-UHFFFAOYSA-N trifluoro-$l^{3}-bromane Chemical compound FBr(F)F FQFKTKUFHWNTBN-UHFFFAOYSA-N 0.000 claims abstract description 32
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 26
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 8
- 239000011737 fluorine Substances 0.000 claims abstract description 8
- 125000002843 carboxylic acid group Chemical group 0.000 claims abstract description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 13
- DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical group FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 claims description 11
- LQULIUZHPYVUHG-UHFFFAOYSA-N 1,1,1-trifluoro-2-(fluoromethoxy)ethane Chemical group FCOCC(F)(F)F LQULIUZHPYVUHG-UHFFFAOYSA-N 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- ICSOIMDWVVEKBW-UHFFFAOYSA-N (2,2,2-trifluoroethoxy)acetic acid Chemical compound OC(=O)COCC(F)(F)F ICSOIMDWVVEKBW-UHFFFAOYSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 239000012442 inert solvent Substances 0.000 claims description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 239000000047 product Substances 0.000 description 24
- 150000001875 compounds Chemical class 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- BLIQUJLAJXRXSG-UHFFFAOYSA-N 1-benzyl-3-(trifluoromethyl)pyrrolidin-1-ium-3-carboxylate Chemical compound C1C(C(=O)O)(C(F)(F)F)CCN1CC1=CC=CC=C1 BLIQUJLAJXRXSG-UHFFFAOYSA-N 0.000 description 8
- 239000003193 general anesthetic agent Substances 0.000 description 8
- 229960002078 sevoflurane Drugs 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000004809 Teflon Substances 0.000 description 6
- 229920006362 Teflon® Polymers 0.000 description 6
- 229940035674 anesthetics Drugs 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 4
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 4
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 4
- 230000003444 anaesthetic effect Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 235000011089 carbon dioxide Nutrition 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 238000004817 gas chromatography Methods 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 238000003682 fluorination reaction Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 2
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 2
- 230000003001 depressive effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 230000026030 halogenation Effects 0.000 description 2
- 238000005658 halogenation reaction Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 2
- 239000003983 inhalation anesthetic agent Substances 0.000 description 2
- 229910001512 metal fluoride Inorganic materials 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000011698 potassium fluoride Substances 0.000 description 2
- 235000003270 potassium fluoride Nutrition 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- PBLGJMMEOGUSID-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoro-2-(fluoromethyl)-2-[1,1,1,3,3,3-hexafluoro-2-(fluoromethyl)propan-2-yl]oxypropane Chemical compound FCC(C(F)(F)F)(C(F)(F)F)OC(CF)(C(F)(F)F)C(F)(F)F PBLGJMMEOGUSID-UHFFFAOYSA-N 0.000 description 1
- HHYFUCXZHKDNPT-UHFFFAOYSA-N 2-(chloromethoxy)-1,1,1,3,3,3-hexafluoropropane Chemical compound FC(F)(F)C(C(F)(F)F)OCCl HHYFUCXZHKDNPT-UHFFFAOYSA-N 0.000 description 1
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 description 1
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010021089 Hyporeflexia Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003874 central nervous system depressant Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000004773 chlorofluoromethyl group Chemical group [H]C(F)(Cl)* 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229960000305 enflurane Drugs 0.000 description 1
- JPGQOUSTVILISH-UHFFFAOYSA-N enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- DLEGDLSLRSOURQ-UHFFFAOYSA-N fluroxene Chemical compound FC(F)(F)COC=C DLEGDLSLRSOURQ-UHFFFAOYSA-N 0.000 description 1
- 229950010045 fluroxene Drugs 0.000 description 1
- 229940005494 general anesthetics Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 1
- 229960002455 methoxyflurane Drugs 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004973 motor coordination Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- IHYNKGRWCDKNEG-UHFFFAOYSA-N n-(4-bromophenyl)-2,6-dihydroxybenzamide Chemical compound OC1=CC=CC(O)=C1C(=O)NC1=CC=C(Br)C=C1 IHYNKGRWCDKNEG-UHFFFAOYSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 150000004812 organic fluorine compounds Chemical class 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 229950011087 perflunafene Drugs 0.000 description 1
- UWEYRJFJVCLAGH-IJWZVTFUSA-N perfluorodecalin Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)[C@@]2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)[C@@]21F UWEYRJFJVCLAGH-IJWZVTFUSA-N 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 101150035983 str1 gene Proteins 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
- C07C51/367—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by introduction of functional groups containing oxygen only in singly bound form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
- C07C41/01—Preparation of ethers
- C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
- C07C41/22—Preparation of ethers by reactions not forming ether-oxygen bonds by introduction of halogens; by substitution of halogen atoms by other halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
- C07C43/04—Saturated ethers
- C07C43/12—Saturated ethers containing halogen
- C07C43/123—Saturated ethers containing halogen both carbon chains are substituted by halogen atoms
Definitions
- the present invention is directed to a method for preparing fluorinated organic compounds. More particularly, the present invention is directed to a method for the fluorodecarboxylation of halogenated aliphatic carboxylic acid compounds to form fluorinated organic products which are useful as inhalation anesthetics.
- Anesthetics belong to a class of biochemical depressant drugs which affect the vital functions of all types of cells, especially nervous tissue cells.
- General anesthetics produce anlgesia, loss of consciousness, diminished reflex activity, and muscular relaxation, with minimal depression of the vital functions.
- Anesthetics may be gaseous (volatile) or fixed (nonvolatile). Gaseous anesthetics are inhaled and enter the bloodstream through the lungs and fixed anesthetics are administered parenterally or through the alimentary canal.
- halogenated anesthetic compounds include halothane (CF 3 CHBrCl) and trichloroethylene (Cl 2 C ⁇ CHCl) as well as halogenated ether compounds such as enflurane (CHF 2 OCF 2 CHClF), fluroxene (CF 3 CH 2 OCH ⁇ CH 2 ), methoxyflurane (Cl 2 CHCF 2 OCH 3 ), and isoflurane (CF 3 CHClOCHF 2 ).
- a particularly useful halogenated ether anesthetic is sevoflurane, (CF 3 ) 2 CHOCHF 2 F, also known as 2-(fluoromethoxy)-1,1,1,3,3,3,-hexafluoropropane or fluoro-methyl-1,1,1,3,3,3-hexafluoro-2-propyl ether.
- Sevoflurane has a very low blood-gas solubility partition coefficient (0.6) which provides rapid equilibrium time, fast induction time and rapid recovery time. These properties make it especially useful for outpatient surgery, see D. F. Halpern, Chemtech. pp. 304-308 (May 1989).
- fluorinated compounds such as sevoflurane tends to be difficult because of the limited number of selective fluorination reactions available.
- Direct fluorination of organic compounds to replace hydrogen is statistical, non-selective and generally accompanied by the formation of many side products.
- fluorinated compounds are usually prepared by first synthesizing a substituted organic intermediate, wherein the substituent group is at the site to be fluorinated, and then displacing the substituent group with a fluoride ion.
- Metal fluorides for example, have been used to displace chlorine substituent groups.
- U.S. Pat. No. 3,683,092 issued to Regan et al., discloses a method for synthesizing sevoflurane which comprises methylation of hexafluorisopropyl alcohol followed by fluorination with either (a) bromine trifluoride or (b) chlorine gas followed by potassium fluoride.
- alkyl carboxylic acids can be fluorodecarboxylated with xenon difluoride (XeF 2 ) in the presence of hydrogen fluoride.
- XeF 2 xenon difluoride
- the use of xenon difluoride on a small scale can be effective, the cost of xenon difluoride makes its use on large scale impractical.
- alkoxyacetic acids are fluorodecarboxylated with xenon difluoride, significant amounts of side products are formed.
- U.S. Pat. No. 4,847,427 discloses a method for preparing fluorocarbon polyethers which comprises neutralizing a perfluorinated carboxylic acid by heating with fluorine in the presence of metal fluoride to replace the carboxylic acid group.
- the present invention provides such an improved procedure for preparing fluorinated compounds from the corresponding carboxylic acids in high yield and purity. More specifically, the present invention provides an improved procedure for the preparation of sevoflurane and other similar types of fluorinated anesthetics.
- the present invention is directed to a method for replacing a carboxylic acid group with a fluorine .[.group.]. in a halogenated aliphatc carboxylic acid compound having the formula R--COOH, to prepare a fluorinated product having the formula, R--F, wherein R is a halogenated aliphatic group including straight- and branched-chain aliphatic groups selected from the group consiting of halogenated aliphatic and .Iadd.halogenated .Iaddend.alkoxysubstituted .[.halogenated.]. aliphatic groups, wherein the method comprises the steps of (a) reacting the halogenated aliphatic carboxylic acid compound with bromine trifluoride, and (b) recovering the fluorinated product.
- the present invention is directed to a method for the fluorodecarboxylation of halogenated aliphatic carboxylic acid compounds to produce fluorinated organic products which are useful as inhalation anesthetics. More particularly, the present invention is directed to a method for replacing a carboxylic acid group with a fluorine .[.group.].
- a fluorinated product having the formula, R--F wherein R is a halogenated aliphatic group including straight- and branched-chain aliphatic groups selected from the group consisting of halogenated aliphatic and .Iadd.halogenated .Iaddend.alkoxysubstituted .[.halogenated.]. aliphatic groups, wherein the method comprises the steps of (a) reacting the halogenated aliphatic carboxylic acid compound with bromine trifluoride, and (b) recovering the fluorinated product.
- R is a halogenated aliphatic group including straight- and branched-chain aliphatic groups selected from the group consisting of halogenated aliphatic and .Iadd.halogenated .Iaddend.alkoxy-substituted .[.halogenated.]. aliphatic groups.
- R is a halogenated lower-alkyl group selected from the group consisting of hexyl, pentyl, butyl, propyl, ethyl, and methyl.
- R is selected from the group consisting of propyl, ethyl, and methyl.
- R is a halogenated lower-alkoxy lower-alkyl group.
- R is a halogenated lower-alkoxy lower-alkyl group wherein the alkoxy group is selected from the group consisting of hexoxy, pentoxy, butoxy, propoxy, ethoxy, and methoxy.
- R is a halogenated lower-alkoxy lower-alkyl group wherein the alkoxy group is selected from the group consisting of hexoxy, pentoxy, butoxy, propoxy, ethoxy, and methoxy, and the alkyl group is selected from the group consisting of hexyl, pentyl, butyl, propyl, ethyl, and methyl.
- halogenated aliphatic carboxylic acid compound means an aliphatic carboxylic acid compound sufficiently halogenated such that the compound will not decompose upon contact with bromine trifluoride. Compounds which are insufficiently halogenated will ignite, burn, or otherwise decompose when contacted with bromine trifluoride and will not provide a fluorinated product.
- halogenated lower-alkyl group and halogenated lower-alkoxy loweralkyl group similarly mean a lower-alkyl group and a lower-alkoxy lower-alkyl group, respectively, sufficiently halogenated such that the respective groups will not decompose upon contact with bromine trifluoride.
- the exact degree of halogenation (the number of halogen atoms present in the molecule) and the exact type of halogenation (the type of halogen atoms present in the molecule) may be varied in the aliphatic carboxylic acid compound in order to obtain the desired final fluorinated product. Such variations are within the capabilities of those skilled in the art without the need for undue experimentation.
- the halogenated aliphatic carboxylic acid compound is a fluorinated aliphatic carboxylic acid compound wherein R is a fluorinated aliphatic group including straight- and branched-chain aliphatic groups selected from the group consisting of fluorinated aliphatic and .Iadd.fluorinated .Iaddend.alkoxy-substituted .[.fluorinated.]. aliphatic groups.
- R is a fluorinated lower-alkyl group selected from the group consisting of hexyl, pentyl, butyl, propyl, ethyl, and methyl.
- R is selected from the group consisting of propyl, ethyl, and methyl.
- R is a fluorinated lower-alkoxy lower-alkyl group.
- R is a fluorinated lower-alkoxy lower-alkyl group wherein the alkoxy group is selected from the group consisting of hexoxy, pentoxy, butoxy, propoxy, ethoxy, and methoxy.
- R is a fluorinated lower-alkoxy lower-alkyl group wherein the alkoxy group is selected from the group consisting of hexoxy, pentoxy, butoxy, propoxy, ethoxy, and methoxy, and the alkyl group is selected from the group consisting of hexyl, pentyl, butyl, propyl, ethyl, and methyl.
- the fluorinated aliphatc carboxylic acid compound is a member selected from the group consisting of .[.1,1,1,3,3,3-hexafluoro-(2-propoxy)acetic.]. .Iadd.2-(1-trifluoromethyl-2,2,2-trifluoroethoxy)acetic .Iaddend.acid and (2,2,2-trifluoroethoxy)acetic acid.
- the fluorinated product is a member selected from the group consisting of 2-fluoromethoxy-1,1,1,3,3,3-hexafluoropropane and fluoromethoxy-2,2,2-trifluoroethane.
- halogenated aliphatic carboxylic acid starting material compound may be substituted with functional groups providing such groups do not react with bromine trifluoride under the reaction conditions.
- non-reactive functional groups which may be present in the starting material include alkoxy groups, aryloxy groups, and mixtures thereof..].
- lower-alkyl means branched- or unbranched-hydrocarbon groups containing from 1 to 6 carbon atoms, and preferably from 1 to 4 carbon atoms.
- lower-alkoxy means branched or unbranched hydrocarboxy groups containing from 1 to 6 carbon atoms, and preferably from 1 to 4 carbon atoms.
- halogen refers to the chemically related elements consisting of fluorine, chlorine, bromine and iodine, and preferably fluorine.
- Bromine trifluoride (BrF 3 ) is a colorless liquid having a melting point of 8.77° C.
- bromine trifluoride will be present in the reaction mixture in a stoichiometric excess compared to the total amount of halogenated aliphatic carboxylic acid compound.
- bromine trifluoride and the halogenated aliphatic carboxylic acid compound will be present in the reaction mixture in an equivalent ratio from about 2:3 to about 3:1, more preferably in an equivalent ratio from about 2:3 to about 1:1, and most preferably in an equivalent ratio of about 2:3, respectively.
- the fluorodecarboxylation reaction may be carried out without solvent.
- the fluorodecarboxylation reaction may be carried out in an inert solvent.
- useful inert solvents include, but are not limited to, highly halogenated compounds such as dichloromethane (methylene chloride), chloroform, carbon tetrachloride, trifluoromethane, perfluorodecalin, and the like, and mixtures thereof.
- the inert solvent is carbon tetrachloride.
- the temperature of the fluorodecarboxylation reaction is not critical, but reaction usually taken place at room temperature.
- the temperature of the reaction mixture may be maintained at just above the boiling point of the fluorinated product to permit distillation of the product concurrent with its synthesis, thereby reducing degradation of the product when exposed to the harsh conditions of the fluorodecarboxylation reaction mixture.
- the fluorinated product may be also be recovered from the reaction mixture in an other known fashion.
- the reaction mixture may be warmed to a temperature sufficient to decompose excess bromine trifluoride by reaction with the solvent (a temperature of about 50° C. is generally sufficient in the presence of carbon tetrachloride).
- the reaction mixture may then be washed with sodium bisulfide (NaHSO 3 ) and the organic layer separated.
- the compounds which may be prepared by the fluorodecarboxylation method of the present invention include compounds which posses very desirable anesthesia activities.
- the anesthetic compounds which may be prepared have central nervous system depressant properties which include analgesia, hypnosis, sedation, increased pain threshold, and barbiturate and/or general anesthetic potentiation.
- Many of the compounds provide highly potent anesthesia with immediate onset and a short duration of action. These properties are highly desirable in circumstances where acute severe pain must be eliminated over a short period of time, such as in anesthesiology.
- the preferred compounds provide reduced rigidity at high doses, superior motor coordination recovery, or less respiratory depressive and/or cardiovascular depressive activity.
- This Example illustrates a method for preparing a halogenated aliphatic carboxylic acid starting material compound according to the present invention.
- This Example illustrates the fluorodecarboxylation of a halogented aliphatic carboxylic acid compound to a fluorinated product according to the method of the present invention.
- This Example illustrates another method for preparing a halogenated aliphatic carboxylic acid starting material compound according to the present invention.
- the combined dichloromethane extracts were concentrated under vacuum to yield 104.3 g of residue which was taken up in acetone (200 ml).
- the acetone mixture was filtered to remove inorganic salts, concentrated under vacuum, then distilled in two fractions (the first fraction distilled at 93°-94.9° C. at 4.6 mm/Hg and the second fraction distilled at 95.1°-95.2° C. at 4.6 mm/Hg).
- the two fractions were combined to afford 87.9 g of the product (2,2,2-trifluoroethoxy)acetic acid.
- This Example illustrates the fluorodecarboxylation of another halogenated aliphatic carboxylic acid compound to a fluorinated product according to the method of the present invention.
- This Example illustrates the fluorodecarboxylation of another halogenated aliphatic carboxylic acid compound to a fluorinated product according to the method of the present invention.
- This Example illustrates the fluorodecarboxylation of a halogenated aliphatic carboxylic acid compound to a fluorinated product using xenon difluoride.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present invention is directed to a method for replacing a carboxylic acid group with a fluorine .[.group.]. in a halogenated aliphatic carboxylic acid compound having the formula, R-COOH, to prepare a fluorinated product having the formula, R-F, wherein R is a halogenated aliphatic group including straight- and branched-chain aliphatic groups selected from the group consisting of halogenated aliphatic and .Iadd.halogenated .Iaddend.alkoxy-substituted .[.halogenated.]. aliphatic groups, wherein the method comprises the step of (a) reacting the halogenated aliphatic carboxylic acid compound with bromine trifluoride, and (b) recovering the fluorinated product.
Description
1. Field of the Invention
The present invention is directed to a method for preparing fluorinated organic compounds. More particularly, the present invention is directed to a method for the fluorodecarboxylation of halogenated aliphatic carboxylic acid compounds to form fluorinated organic products which are useful as inhalation anesthetics.
2. Description of the Prior Art
Anesthetics belong to a class of biochemical depressant drugs which affect the vital functions of all types of cells, especially nervous tissue cells. General anesthetics produce anlgesia, loss of consciousness, diminished reflex activity, and muscular relaxation, with minimal depression of the vital functions. Anesthetics may be gaseous (volatile) or fixed (nonvolatile). Gaseous anesthetics are inhaled and enter the bloodstream through the lungs and fixed anesthetics are administered parenterally or through the alimentary canal.
Many currently used gaseous anesthetics are halogenated compounds. These compounds tend to cause less metabolic disturbance and are less flammable than traditional gaseous anesthetic compounds such as ether and cyclopropane. Examples of halogenated anesthetic compounds include halothane (CF3 CHBrCl) and trichloroethylene (Cl2 C═CHCl) as well as halogenated ether compounds such as enflurane (CHF2 OCF2 CHClF), fluroxene (CF3 CH2 OCH═CH2), methoxyflurane (Cl2 CHCF2 OCH3), and isoflurane (CF3 CHClOCHF2).
A particularly useful halogenated ether anesthetic is sevoflurane, (CF3)2 CHOCHF2 F, also known as 2-(fluoromethoxy)-1,1,1,3,3,3,-hexafluoropropane or fluoro-methyl-1,1,1,3,3,3-hexafluoro-2-propyl ether. Sevoflurane has a very low blood-gas solubility partition coefficient (0.6) which provides rapid equilibrium time, fast induction time and rapid recovery time. These properties make it especially useful for outpatient surgery, see D. F. Halpern, Chemtech. pp. 304-308 (May 1989).
The preparation of fluorinated compounds such as sevoflurane tends to be difficult because of the limited number of selective fluorination reactions available. Direct fluorination of organic compounds to replace hydrogen is statistical, non-selective and generally accompanied by the formation of many side products. Hence fluorinated compounds are usually prepared by first synthesizing a substituted organic intermediate, wherein the substituent group is at the site to be fluorinated, and then displacing the substituent group with a fluoride ion. Metal fluorides, for example, have been used to displace chlorine substituent groups.
U.S. Pat. No. 3,683,092, issued to Regan et al., discloses a method for synthesizing sevoflurane which comprises methylation of hexafluorisopropyl alcohol followed by fluorination with either (a) bromine trifluoride or (b) chlorine gas followed by potassium fluoride.
U.S. Pat. No. 4,469,898, issued to Coon et al., discloses a method for synthesizing sevoflurane which comprises mixing hexafluoroisopropyl alcohol, formaldehyde, hydrogen fluoride, and a protonating, dehydrating and fluoride ion generating agent.
U.S. Pat. No. 4,874,901, issued to Halpern et al., discloses a method for fluorinating halogenated ether compounds. In particular, compounds such as sevoflurane can be prepared by reacting chloromethyl hexafluoroisopropyl ether with either potassium fluoride or sodium fluoride.
Patrick et al., J. Org. Chem., 48, 4158-4159 (1983), reports that alkyl carboxylic acids can be fluorodecarboxylated with xenon difluoride (XeF2) in the presence of hydrogen fluoride. Although the use of xenon difluoride on a small scale can be effective, the cost of xenon difluoride makes its use on large scale impractical. Furthermore, when alkoxyacetic acids are fluorodecarboxylated with xenon difluoride, significant amounts of side products are formed.
U.S. Pat. No. 4,847,427, issued to Nappa, discloses a method for preparing fluorocarbon polyethers which comprises neutralizing a perfluorinated carboxylic acid by heating with fluorine in the presence of metal fluoride to replace the carboxylic acid group.
While the above methods are useful for preparing certain fluorinated compounds, these methods are complex, expensive, and often provide fluorinated products in low yield together with considerable amounts of side products. Hence there is a need for improved procedures for the preparation of fluorinated compounds. The present invention provides such an improved procedure for preparing fluorinated compounds from the corresponding carboxylic acids in high yield and purity. More specifically, the present invention provides an improved procedure for the preparation of sevoflurane and other similar types of fluorinated anesthetics.
The present invention is directed to a method for replacing a carboxylic acid group with a fluorine .[.group.]. in a halogenated aliphatc carboxylic acid compound having the formula R--COOH, to prepare a fluorinated product having the formula, R--F, wherein R is a halogenated aliphatic group including straight- and branched-chain aliphatic groups selected from the group consiting of halogenated aliphatic and .Iadd.halogenated .Iaddend.alkoxysubstituted .[.halogenated.]. aliphatic groups, wherein the method comprises the steps of (a) reacting the halogenated aliphatic carboxylic acid compound with bromine trifluoride, and (b) recovering the fluorinated product.
The present invention is directed to a method for the fluorodecarboxylation of halogenated aliphatic carboxylic acid compounds to produce fluorinated organic products which are useful as inhalation anesthetics. More particularly, the present invention is directed to a method for replacing a carboxylic acid group with a fluorine .[.group.]. in a halogenated aliphatic carboxylic acid compound having the formula, R--COOH, to prepare a fluorinated product having the formula, R--F, wherein R is a halogenated aliphatic group including straight- and branched-chain aliphatic groups selected from the group consisting of halogenated aliphatic and .Iadd.halogenated .Iaddend.alkoxysubstituted .[.halogenated.]. aliphatic groups, wherein the method comprises the steps of (a) reacting the halogenated aliphatic carboxylic acid compound with bromine trifluoride, and (b) recovering the fluorinated product.
More particularly, the present invention is directed at a fluorodecarboxylation method illustrated by equation (1) set out below: ##STR1## wherin R is a halogenated aliphatic group including straight- and branched-chain aliphatic groups selected from the group consisting of halogenated aliphatic and .Iadd.halogenated .Iaddend.alkoxy-substituted .[.halogenated.]. aliphatic groups. In a preferred embodiment, R is a halogenated lower-alkyl group selected from the group consisting of hexyl, pentyl, butyl, propyl, ethyl, and methyl. In a more preferred embodiment, R is selected from the group consisting of propyl, ethyl, and methyl.
In another preferred embodiment, R is a halogenated lower-alkoxy lower-alkyl group. In a more preferred embodiment, R is a halogenated lower-alkoxy lower-alkyl group wherein the alkoxy group is selected from the group consisting of hexoxy, pentoxy, butoxy, propoxy, ethoxy, and methoxy. In a most preferred embodiment, R is a halogenated lower-alkoxy lower-alkyl group wherein the alkoxy group is selected from the group consisting of hexoxy, pentoxy, butoxy, propoxy, ethoxy, and methoxy, and the alkyl group is selected from the group consisting of hexyl, pentyl, butyl, propyl, ethyl, and methyl.
The term "halogenated aliphatic carboxylic acid compound", as used herein, means an aliphatic carboxylic acid compound sufficiently halogenated such that the compound will not decompose upon contact with bromine trifluoride. Compounds which are insufficiently halogenated will ignite, burn, or otherwise decompose when contacted with bromine trifluoride and will not provide a fluorinated product. The terms "halogenated lower-alkyl group" and "halogenated lower-alkoxy loweralkyl group" similarly mean a lower-alkyl group and a lower-alkoxy lower-alkyl group, respectively, sufficiently halogenated such that the respective groups will not decompose upon contact with bromine trifluoride. The exact degree of halogenation (the number of halogen atoms present in the molecule) and the exact type of halogenation (the type of halogen atoms present in the molecule) may be varied in the aliphatic carboxylic acid compound in order to obtain the desired final fluorinated product. Such variations are within the capabilities of those skilled in the art without the need for undue experimentation.
In another preferred embodiment, the halogenated aliphatic carboxylic acid compound is a fluorinated aliphatic carboxylic acid compound wherein R is a fluorinated aliphatic group including straight- and branched-chain aliphatic groups selected from the group consisting of fluorinated aliphatic and .Iadd.fluorinated .Iaddend.alkoxy-substituted .[.fluorinated.]. aliphatic groups. In a more preferred embodiment, R is a fluorinated lower-alkyl group selected from the group consisting of hexyl, pentyl, butyl, propyl, ethyl, and methyl. In a most preferred embodiment, R is selected from the group consisting of propyl, ethyl, and methyl.
In another preferred embodiment, R is a fluorinated lower-alkoxy lower-alkyl group. In a more preferred embodiment, R is a fluorinated lower-alkoxy lower-alkyl group wherein the alkoxy group is selected from the group consisting of hexoxy, pentoxy, butoxy, propoxy, ethoxy, and methoxy. In a most preferred embodiment, R is a fluorinated lower-alkoxy lower-alkyl group wherein the alkoxy group is selected from the group consisting of hexoxy, pentoxy, butoxy, propoxy, ethoxy, and methoxy, and the alkyl group is selected from the group consisting of hexyl, pentyl, butyl, propyl, ethyl, and methyl.
In a most preferred embodiment, the fluorinated aliphatc carboxylic acid compound is a member selected from the group consisting of .[.1,1,1,3,3,3-hexafluoro-(2-propoxy)acetic.]. .Iadd.2-(1-trifluoromethyl-2,2,2-trifluoroethoxy)acetic .Iaddend.acid and (2,2,2-trifluoroethoxy)acetic acid. In a most preferred embodiment, the fluorinated product is a member selected from the group consisting of 2-fluoromethoxy-1,1,1,3,3,3-hexafluoropropane and fluoromethoxy-2,2,2-trifluoroethane.
.[.The halogenated aliphatic carboxylic acid starting material compound may be substituted with functional groups providing such groups do not react with bromine trifluoride under the reaction conditions. In general, non-reactive functional groups which may be present in the starting material include alkoxy groups, aryloxy groups, and mixtures thereof..].
The term "lower-alkyl", as used herein, means branched- or unbranched-hydrocarbon groups containing from 1 to 6 carbon atoms, and preferably from 1 to 4 carbon atoms. The term "lower-alkoxy", as used herein, means branched or unbranched hydrocarboxy groups containing from 1 to 6 carbon atoms, and preferably from 1 to 4 carbon atoms. The term "halogen", as used herein, refers to the chemically related elements consisting of fluorine, chlorine, bromine and iodine, and preferably fluorine.
Bromine trifluoride (BrF3) is a colorless liquid having a melting point of 8.77° C. In general, bromine trifluoride will be present in the reaction mixture in a stoichiometric excess compared to the total amount of halogenated aliphatic carboxylic acid compound. A 1:1 molar ratio of bromine trifluoride to halogenated aliphatic carboxylic acid compound, respectively, represents a 3:1 equivalent ratio with respect to fluorine. In a preferred embodiment, bromine trifluoride and the halogenated aliphatic carboxylic acid compound will be present in the reaction mixture in an equivalent ratio from about 2:3 to about 3:1, more preferably in an equivalent ratio from about 2:3 to about 1:1, and most preferably in an equivalent ratio of about 2:3, respectively.
When the halogenated aliphatic carboxylic acid starting material compound is liquid, the fluorodecarboxylation reaction may be carried out without solvent. When the halogenated aliphatic carboxylic acid compound is not liquid, the fluorodecarboxylation reaction may be carried out in an inert solvent. Useful inert solvents include, but are not limited to, highly halogenated compounds such as dichloromethane (methylene chloride), chloroform, carbon tetrachloride, trifluoromethane, perfluorodecalin, and the like, and mixtures thereof. In a preferred embodiment, the inert solvent is carbon tetrachloride.
The temperature of the fluorodecarboxylation reaction is not critical, but reaction usually taken place at room temperature. The temperature of the reaction mixture may be maintained at just above the boiling point of the fluorinated product to permit distillation of the product concurrent with its synthesis, thereby reducing degradation of the product when exposed to the harsh conditions of the fluorodecarboxylation reaction mixture.
The fluorinated product may be also be recovered from the reaction mixture in an other known fashion. For example, the reaction mixture may be warmed to a temperature sufficient to decompose excess bromine trifluoride by reaction with the solvent (a temperature of about 50° C. is generally sufficient in the presence of carbon tetrachloride). The reaction mixture may then be washed with sodium bisulfide (NaHSO3) and the organic layer separated.
The compounds which may be prepared by the fluorodecarboxylation method of the present invention include compounds which posses very desirable anesthesia activities. In particular, the anesthetic compounds which may be prepared have central nervous system depressant properties which include analgesia, hypnosis, sedation, increased pain threshold, and barbiturate and/or general anesthetic potentiation. Many of the compounds provide highly potent anesthesia with immediate onset and a short duration of action. These properties are highly desirable in circumstances where acute severe pain must be eliminated over a short period of time, such as in anesthesiology. The preferred compounds provide reduced rigidity at high doses, superior motor coordination recovery, or less respiratory depressive and/or cardiovascular depressive activity.
The present invention is further illustrated by the following examples which are presented for the purpose of demonstrating, but not limiting, the method of this invention.
This Example illustrates a method for preparing a halogenated aliphatic carboxylic acid starting material compound according to the present invention.
A solution of .[.1,1,1,3,3,3-hexafluoro-2-propanol.]. .Iadd.1-trifluoromethyl-2,2,2-trifluoroethanol .Iaddend.(42.1 g, 0.25 mole, Aldrich) and bromoacetic acid (69.5 g, 0.5 mole) in water (150 ml) was brought to pH 12.5 by addition of 50% sodium hydroxide solution (47 g) with stirring and maintained at pH 12.5±0.5 by addition of 50% sodium hydroxide solution, as needed. The reaction solution was heated to reflux for 3.5 hours, then cooled. A solution of 37% hydrochloric acid (61.3 g) and 8% hydrochloric acid (27.1 g) was added to the reaction solution to bring the pH to 1. The reaction solution was then distilled (azeotrope) under a Dean-Stark trap. The lower layer in the Dean-Stark trap was separated (53.2 g) and sublimed (88° C., 7-9 mm, dry ice/acetone trap) to yield 27.12 g (48% yield) of .[.1,1,1,3,3,3-hexafluoro-(2-propoxy)acetic.]. .Iadd.2-(1-trifluoromethyl-2,2,2-trifluoroethoxy)acetic .Iaddend.acid having mp. 60°-62° C.
When chloracetic acid was substituted from bromoacetic acid in the above procedure, a 19.8% yield of .[.1,1,1,3,3,3-hexafluoro-(2-propoxy)acetic.]. .Iadd.2-(1-trifluoromethyl-2,2,2-trifluoroethoxy)acetic .Iaddend.acid was obtained.
This Example illustrates the fluorodecarboxylation of a halogented aliphatic carboxylic acid compound to a fluorinated product according to the method of the present invention.
A solution of .[.1,1,1,3,3,3-hexafluoro-(2-propoxy)acetic.]. .Iadd.2-(1-trifluoromethyl-2,2,2-trifluoroethoxy)acetic .Iaddend.acid (2.26 g, 0.01 mole) from Example 1 in carbon tetrachloride (100 g) was introduced into a 400 ml Teflon vessel equipped with an air-tight cover, a thermometer, a Teflon stirring bar, a bromine trifluoride inlet and a gas outlet connected to a dry ice/acetone trap. Bromine trifluoride (1.05 g, 0.42 ml, 0.0067 mole) was slowly added to the solution. When addition of bromine trifluoride was complete, the reaction mixture was heated gently to just under reflux for 5 hours to remove volatiles and decompose excess bromine trifluoride (by reaction with carbon tetrachloride). The reaction mixture was then cooled and washed with dilute sodium bisulfite (NaHSO3) solution. The organic layer was separated and analysis by gas chromatography showed a 75% yield of the product 2-fluoromethoxy-1,1,1,3,3,3-hexafluoropropane.
This Example illustrates another method for preparing a halogenated aliphatic carboxylic acid starting material compound according to the present invention.
A solution of 2,2,2,-trifluoroethanol (84 g, 1 mole, Aldrich) and chloroacetic and (189 g, 2 moles) in water (600 ml) was brought to pH>13 by addition of 50% sodium hydroxide solution with stirring and maintained at pH>13 by addition of 50% sodium hydroxide solution, as needed. The reaction solution was heated to 84°-93° C. for 3.5 hours, maintained at 90°-100° C. overnight, then cooled. Concentrated hydrochloric acid was added to the reaction solution to bring the pH to about 1. The reaction solution was then heated until all 2,2,2-trifluoroethanol was distilled. The reaction solution was then cooled and extracted 12 times with dichloromethane (250 ml portions). The combined dichloromethane extracts were concentrated under vacuum to yield 104.3 g of residue which was taken up in acetone (200 ml). The acetone mixture was filtered to remove inorganic salts, concentrated under vacuum, then distilled in two fractions (the first fraction distilled at 93°-94.9° C. at 4.6 mm/Hg and the second fraction distilled at 95.1°-95.2° C. at 4.6 mm/Hg). The two fractions were combined to afford 87.9 g of the product (2,2,2-trifluoroethoxy)acetic acid.
Anal. Calculated for C4 H5 F3 O2 : C, 30.38% H, 3.16%. Found C, 30.35%; H, 3.00%.
This Example illustrates the fluorodecarboxylation of another halogenated aliphatic carboxylic acid compound to a fluorinated product according to the method of the present invention.
A solution of (2,2,2-trifluoroethoxy)acetic acid (2.2 g, 0.0014 mole) from Example 3 in carbon tetrachloride (80 g) was introduced into a 400 ml Teflon vessel equipped with an air-tight cover, a thermometer, a Teflon stirring bar, a bromine trifluoride inlet and a gas outlet connected to a dry ice/acetone trap. Bromine trifluoride (5.7 g, 2 ml, 0.041 mole) was slowly added to the solution. When addition of bromine trifluoride was complete, the reaction mixture was heated gently to just under reflux for 5 hours to remove volatiles and decompose excess bromine trifluoride (by reaction with carbon tetrachloride). The reaction mixture was then cooled and washed with dilute sodium bisulfite solution. The organic layer was separated and analysis by gas chromatography showed a 90% yield of the product fluoromethoxy-2,2,2-trifluoroethane.
This Example illustrates the fluorodecarboxylation of another halogenated aliphatic carboxylic acid compound to a fluorinated product according to the method of the present invention.
A solution of (2,2,2-trifluoroethoxy)acetic acid (20.0 g, 0.127 mole) from Example 3 in dichloromethane (229.3 g) was introduced into a 400 ml Teflon vessel equipped with an air-tight cover, a thermometer, a Teflon stirring bar, a bromine trifluoride inlet and a gas outlet connected to a dry ice/acetone trap. The vessel was placed in a water bath at room temperature and bromine trifluoride (11.4 g, 4 ml, 0.084 mole) was slowly added to the solution. When addition of bromine trifluoride was complete, the reaction mixture was stirred overnight, then washed with dilute sodium bisulfite solution. The organic layer was separated (194 g) and analysis by gas chromatography showed a 100% yield of the product fluoromethoxy-2,2,2-trifluoroethane.
This Example illustrates the fluorodecarboxylation of a halogenated aliphatic carboxylic acid compound to a fluorinated product using xenon difluoride.
Xenon difluoride (2 g, 0.012 mole) was slowly added over a period of one hour to a solution of (2,2,2-trifluoroethoxy)acetic acid (1.9 g, 0.012 mole) from Example 3 in carbon tetrachloride (20 g) in a glass vessel. When addition of xenon difluoride was complete, the reaction mixture was heated to 45° C. for 0.5 hour, then cooled. The reaction mixture was then diluted to provide 0.44 of product (25% yield). Gas chromatography analysis showed the major product to be fluoromethoxy-2,2,2-trifluoroethane contaminated with significant amounts of CF3 CH2 OCF2 H, CF3 CHFOCH2 F, CF2 Cl2, and CFCl3.
It will be understood that the embodiments described herein are merely exemplary and that a person skilled in the art may make many variations and modifications without departing from the spirit and scope of the invention. All such modifications and variations are intended to be included within the scope of the invention as defined in the appended claims.
Claims (20)
1. A method for replacing a carboxylic acid group with a fluorine .[.group.]. in a halogenated aliphatic carboxylic acid compound having the formula, R-COOH, to prepare a fluorinated product having the formula, R-F, wherein R is a halogenated aliphatic group including straight- and branched-chain aliphatic groups selected from the group consisting of halogenated aliphatic and .Iadd.halogenated .Iaddend.alkoxy-substituted .[.halogenated.]. aliphatic groups, wherein the method comprises the steps of:
(a) reacting the halogenated aliphatic carboxylic acid compound with bromine trifluoride; and
(b) recovering the fluorinated product.
2. The method according to claim 1, wherein R is a halogenated aliphatic group selected from the group consisting of hexyl, pentyl, butyl, propyl, ethyl, and methyl.
3. The method according to claim 1, wherein R is a halogenated lower-alkoxy lower-alkyl group.
4. The method according to claim 3, wherein the lower-alkoxy group is selected from the group consisting of hexoxy, pentoxy, butoxy, propoxy, ethoxy, and methoxy.
5. The method according to claim 1, wherein bromine trifluoride and the halogenated aliphatic carboxylic acid compound are present in an equivalent ratio from about 2:3 to about 3:1 respectively.
6. The method according to claim 5, wherein bromine trifluoride and the halogenated aliphatic carboxylic acid compound are present in an equivalent ratio from about 2:3 to about 1:1, respectively.
7. The method according to claim 1, wherein the halogenated aliphatic carboxylic acid compound is reacted with bromine trifluoride in an inert solvent.
8. The method according to claim 7, wherein the inert solvent is selected from the group consisting of dichloromethane, chloroform, carbon tetrachloride, and mixtures thereof.
9. The method according to claim 1, wherein the halogenated aliphatic carboxylic acid compound is a fluorinated aliphatic carboxylic acid compound.
10. The method according to claim 9, wherein R is a fluorinated aliphatic group selected from the group consisting of hexyl, pentyl, butyl, propyl, ethyl, and methyl.
11. The method according to claim 9, wherein R is a fluorinated lower-alkoxy lower-alkyl group.
12. The method according to claim 11, wherein the lower-alkoxy group is selected from the group consisting of hexoxy, pentoxy, butoxy, propoxy, ethoxy, and methoxy.
13. The method according to claim 9, wherein bromine trifluoride and the fluorinated aliphatic carboxylic acid compound are present in an equivalent ratio from about 2:3 to about 3:1, respectively.
14. The method according to claim 13, wherein bromine trifluoride and the fluorinated aliphatic carboxylic acid compound are present in an equivalent ratio from about 2:3 to about 1:1, respectively.
15. The method according to claim 9, wherein the fluorinated aliphatic carboxylic acid compound is reacted with bromine trifluoride in an inert solvent.
16. The method according to claim 15, wherein the inert solvent is selected from the group consisting of dichloromethane, chloroform, carbon tetrachloride, and mixtures thereof.
17. The method according to claim 9, wherein the fluorinated aliphatic carboxylic acid compound is .[.1,1,1,3,3,3-hexafluoro-(2-propoxy)acetic.]. .Iadd.2-(1-trifluoromethyl-2,2,2-trifluoroethoxy)acetic .Iaddend.acid.
18. The method according to claim 9, wherein the fluorinated aliphatic carboxylic acid compound is (2,2,2-trifluoroethoxy)acetic acid.
19. The method according to claim 9, wherein the fluorinated product is 2-fluoromethoxy-1,1,1,3,3,3-hexafluoropropane.
20. The method according to claim 9, wherein the fluorinated product is fluoromethoxy-2,2,2-trifluoroethane.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/340,960 USRE35568E (en) | 1990-01-16 | 1994-11-16 | Method for fluorodecarboxylation |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/464,834 US4996371A (en) | 1990-01-16 | 1990-01-16 | Method for fluorodecarboxylation |
| US08/340,960 USRE35568E (en) | 1990-01-16 | 1994-11-16 | Method for fluorodecarboxylation |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/464,834 Reissue US4996371A (en) | 1990-01-16 | 1990-01-16 | Method for fluorodecarboxylation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| USRE35568E true USRE35568E (en) | 1997-07-22 |
Family
ID=23845428
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/464,834 Ceased US4996371A (en) | 1990-01-16 | 1990-01-16 | Method for fluorodecarboxylation |
| US08/340,960 Expired - Lifetime USRE35568E (en) | 1990-01-16 | 1994-11-16 | Method for fluorodecarboxylation |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/464,834 Ceased US4996371A (en) | 1990-01-16 | 1990-01-16 | Method for fluorodecarboxylation |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US4996371A (en) |
| EP (1) | EP0437689B1 (en) |
| JP (1) | JPH0637400B2 (en) |
| CA (1) | CA2027522C (en) |
| DE (1) | DE69022707T2 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6245949B1 (en) | 2000-06-01 | 2001-06-12 | Abbott Laboratories | Synthetic method for the fluoromethylation of alcohols |
| US6271422B1 (en) | 2000-06-01 | 2001-08-07 | Abbott Laboratories | Method for fluoromethylation of alcohols via halogenative decarboxylation |
| US6303831B1 (en) | 2000-06-01 | 2001-10-16 | Abbott Laboratories | Synthetic method for fluoromethylation of halogenated alcohols |
| US20100010255A1 (en) * | 2006-07-06 | 2010-01-14 | Daikin Industries Ltd | Novel alpha-fluoromethoxycarboxylic ester, process for producing the alpha-fluoromethoxycarboxylic ester, and process for producing sevoflurane |
| US8013182B2 (en) * | 2007-11-13 | 2011-09-06 | Daikin Industries, Ltd. | Carboxylic acid ester, use of the same, and method for producing the same |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5637776A (en) * | 1992-12-10 | 1997-06-10 | Imperial Chemical Industries Plc | Production of hydrofluorocarbons |
| US5391579A (en) * | 1993-01-28 | 1995-02-21 | University Of Iowa Research Foundation | Deuterated sevoflurane as an inhalational anesthetic |
| US5492111A (en) * | 1993-01-28 | 1996-02-20 | University Of Iowa Research Foundation | Method of elimination of volatile degradation products of sevoflurane during anesthesia |
| US5969193A (en) * | 1997-08-18 | 1999-10-19 | Medeva Pharmaceuticals Pa, Inc. | Method for the preparation of sevoflurane |
| US7138551B2 (en) * | 2004-11-05 | 2006-11-21 | E. I. Du Pont De Nemours And Company | Purification of fluorinated alcohols |
| CA2605246C (en) * | 2005-04-18 | 2015-11-17 | Minrad Inc. | Preparation of sevoflurane with negligible water content |
| PT105138B (en) * | 2010-06-01 | 2012-11-06 | Hovione Farmaciencia S A | METHOD FOR THE PREPARATION OF BIOLOGICALLY ACTIVE MONOFLUOROMETHYL ORGANIC COMPOUNDS |
| PT105723B (en) | 2011-05-26 | 2014-03-24 | Hovione Farmaci Ncia S A | METHOD FOR THE PREPARATION OF BIOLOGICALLY ACTIVE ORGANIC COMPOUNDS |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3683092A (en) * | 1970-07-31 | 1972-08-08 | Baxter Laboratories Inc | Method of anesthesia |
| US4469898A (en) * | 1979-12-26 | 1984-09-04 | Baxter Travenol Laboratories, Inc. | Method of synthesizing fluoromethylhexafluoroisopropyl ether |
| US4847427A (en) * | 1988-04-13 | 1989-07-11 | E. I. Du Pont De Nemours And Company | Process for preparing fluorocarbon polyethers |
| US4874901A (en) * | 1988-05-06 | 1989-10-17 | Boc, Inc. | Process for the production of polyfluorinated ethers |
| US4874902A (en) * | 1988-05-20 | 1989-10-17 | Boc, Inc. | Method for the preparation of fluoromethyl 1,1,1,3,3,3-hexafluoro-2-propyl ether |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4250334A (en) * | 1979-12-26 | 1981-02-10 | Baxter Travenol Laboratories, Inc. | Method of synthesizing fluoromethylhexafluoroisopropyl ether |
-
1990
- 1990-01-16 US US07/464,834 patent/US4996371A/en not_active Ceased
- 1990-10-12 CA CA002027522A patent/CA2027522C/en not_active Expired - Lifetime
- 1990-10-19 JP JP2281726A patent/JPH0637400B2/en not_active Expired - Lifetime
- 1990-10-30 DE DE69022707T patent/DE69022707T2/en not_active Expired - Lifetime
- 1990-10-30 EP EP90120827A patent/EP0437689B1/en not_active Expired - Lifetime
-
1994
- 1994-11-16 US US08/340,960 patent/USRE35568E/en not_active Expired - Lifetime
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3683092A (en) * | 1970-07-31 | 1972-08-08 | Baxter Laboratories Inc | Method of anesthesia |
| US4469898A (en) * | 1979-12-26 | 1984-09-04 | Baxter Travenol Laboratories, Inc. | Method of synthesizing fluoromethylhexafluoroisopropyl ether |
| US4847427A (en) * | 1988-04-13 | 1989-07-11 | E. I. Du Pont De Nemours And Company | Process for preparing fluorocarbon polyethers |
| US4874901A (en) * | 1988-05-06 | 1989-10-17 | Boc, Inc. | Process for the production of polyfluorinated ethers |
| US4874902A (en) * | 1988-05-20 | 1989-10-17 | Boc, Inc. | Method for the preparation of fluoromethyl 1,1,1,3,3,3-hexafluoro-2-propyl ether |
Non-Patent Citations (5)
| Title |
|---|
| Can. J. of Chem., vol. 64, (1986) pp. 138 141, Patrick et al., Replacement of the Carboxylic Acid Function with fluoride . * |
| Can. J. of Chem., vol. 64, (1986) pp. 138-141, Patrick et al., "Replacement of the Carboxylic Acid Function with fluoride". |
| Chem tech, May 1989, pp. 304, 308, Halpern. * |
| J. Org. Chem, vol. 48, (1983) pp. 4158 4159, Patrick et al. * |
| J. Org. Chem, vol. 48, (1983) pp. 4158-4159, Patrick et al. |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6245949B1 (en) | 2000-06-01 | 2001-06-12 | Abbott Laboratories | Synthetic method for the fluoromethylation of alcohols |
| US6271422B1 (en) | 2000-06-01 | 2001-08-07 | Abbott Laboratories | Method for fluoromethylation of alcohols via halogenative decarboxylation |
| US6303831B1 (en) | 2000-06-01 | 2001-10-16 | Abbott Laboratories | Synthetic method for fluoromethylation of halogenated alcohols |
| US20100010255A1 (en) * | 2006-07-06 | 2010-01-14 | Daikin Industries Ltd | Novel alpha-fluoromethoxycarboxylic ester, process for producing the alpha-fluoromethoxycarboxylic ester, and process for producing sevoflurane |
| US8022245B2 (en) * | 2006-07-06 | 2011-09-20 | Daikin Industries, Ltd. | Alpha-fluoromethoxycarboxylic ester, process for producing the alpha-fluoromethoxycarboxylic ester, and process for producing sevoflurane |
| US8013182B2 (en) * | 2007-11-13 | 2011-09-06 | Daikin Industries, Ltd. | Carboxylic acid ester, use of the same, and method for producing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2027522C (en) | 1997-09-30 |
| JPH03220132A (en) | 1991-09-27 |
| JPH0637400B2 (en) | 1994-05-18 |
| DE69022707T2 (en) | 1996-04-04 |
| EP0437689A1 (en) | 1991-07-24 |
| DE69022707D1 (en) | 1995-11-02 |
| EP0437689B1 (en) | 1995-09-27 |
| CA2027522A1 (en) | 1991-07-17 |
| US4996371A (en) | 1991-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| USRE35568E (en) | Method for fluorodecarboxylation | |
| US7202386B2 (en) | Method for the preparation of sevoflurane | |
| EP2069278B1 (en) | Process for the preparation of chloromethyl 2,2,2-trifluoro-1-(trifluoromethyl) ethyl ether | |
| US6303831B1 (en) | Synthetic method for fluoromethylation of halogenated alcohols | |
| AU2001265158B2 (en) | Synthetic method for the fluoromethylation of alcohols | |
| AU2001265129A1 (en) | Synthetic method for fluoromethylation of halogenated alcohols | |
| EP1286939B1 (en) | Method for fluoromethylation of alcohols via halogenative decarboxylation | |
| AU2001261565A1 (en) | Method for fluoromethylation of alcohols via halogenative decarboxylation | |
| HK1135087B (en) | Process for the preparation of chloromethyl 2,2,2-trifluoro-1-(trifluoromethyl) ethyl ether |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| FPAY | Fee payment |
Year of fee payment: 12 |